Neurofilament light chains (NfL) have emerged as potential biomarkers associated with disease activity in CIDP, but no biomarker has yet been validated to reliably reflect the underlying pathophysiology or predict treatment responses in clinical practice [4, 5, 6, 7, 8]. The gene discussed is NEFL; the disease is chronic inflammatory demyelinating polyradiculoneuropathy.